Скачать или смотреть Anti-IL5 Therapy Reduces Severe COPD Exacerbations: Real-World Evidence from Belgian Study

Discover how anti-IL5 therapy is revolutionizing the treatment of chronic obstructive pulmonary disease (COPD) and asthma. A groundbreaking Belgian study reveals that targeting eosinophilic inflammation with mepolizumab or benralizumab significantly cuts severe exacerbations, reducing hospitalizations by 56%. This real-world evidence highlights the therapy's effectiveness across diverse lung disease populations, including current smokers and patients with overlapping COPD and asthma. Learn how this targeted approach can improve patient outcomes and reduce healthcare burden. Whether you're a patient, caregiver, or healthcare professional, this video provides essential insights into the latest advancements in COPD and asthma management. Don't miss out on this critical information that could change the way we treat obstructive lung diseases!